{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:04:26Z","timestamp":1792785866352,"version":"4.5.0"},"reference-count":44,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2022,6,3]],"date-time":"2022-06-03T00:00:00Z","timestamp":1654214400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000024","name":"CIHR","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004411","name":"HSFC","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004411","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008349","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008349","id-type":"DOI","asserted-by":"publisher"}]},{"name":"AGEN"},{"DOI":"10.13039\/501100014091","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014091","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004326","name":"Bayer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Biotie"},{"DOI":"10.13039\/100008021","name":"BMS","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008021","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002336","name":"Daiichi Sankyo Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010891","name":"Portola Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010891","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017931","name":"Cytori","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017931","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008897","name":"Janssen Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100023331","name":"Leo Pharma","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100023331","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015237","name":"Medicines Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015237","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011725","name":"Servier","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol Meyers Squibb","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,12,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aim<\/jats:title>\n                    <jats:p>To evaluate the ability of the DrugSorb\u2122-AntiThrombotic Removal (ATR) haemoadsorption device utilizing porous polymer bead sorbent technology to remove three commonly used antithrombotic drugs from whole blood.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>We evaluated the removal of apixaban, rivaroxaban, and ticagrelor by the DrugSorb-ATR haemoadsorption device in a benchtop clinical scale model using bovine whole blood. Blood spiked at clinically relevant concentrations of an antithrombotic agent was continuously circulated through a 300-mL DrugSorb-ATR haemoadsorption device at a flow rate of 300\u00a0mL\/min. Drug concentration was monitored over 6\u00a0h to evaluate drug removal. Results were compared with a control circuit without the haemoadsorption device. Removal rates at 30, 60, 120, and 360 minutes were: apixaban: 81.5%, 96.3%, 99.3% &amp;gt;99.8%; rivaroxaban: 80.7%, 95.1%, 98.9%, &amp;gt;99.5%; ticagrelor: 62.5%; 75%, 86.6%, &amp;gt;95% (all P\u00a0&amp;lt;0.0001 vs. control). Blood pH and haematological parameters were not significantly affected by the DrugSorb-ATR haemoadsorption device when compared with the control circuit.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>DrugSorb-ATR efficiently removes apixaban, rivaroxaban, and ticagrelor in a clinical-scale benchtop recirculation circuit with the bulk of removal occurring in the first 60 minutes. The clinical implications of these findings are currently investigated in patients undergoing on-pump cardiothoracic surgery in two US pivotal trials (ClinicalTrials.gov Identifiers: NCT04976530 and NCT05093504).<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ehjcvp\/pvac036","type":"journal-article","created":{"date-parts":[[2022,6,3]],"date-time":"2022-06-03T10:53:25Z","timestamp":1654253605000},"page":"847-856","source":"Crossref","is-referenced-by-count":44,"title":["Antithrombotic drug removal from whole blood using Haemoadsorption with a porous polymer bead sorbent"],"prefix":"10.1093","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6919-1106","authenticated-orcid":false,"given":"Ritu","family":"Tripathi","sequence":"first","affiliation":[{"name":"CytoSorbents Medical Inc. 305 College Road E, Princeton, NJ-08540 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesus","family":"Morales","sequence":"additional","affiliation":[{"name":"CytoSorbents Medical Inc. 305 College Road E, Princeton, NJ-08540 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Lee","sequence":"additional","affiliation":[{"name":"CytoSorbents Medical Inc. 305 College Road E, Princeton, NJ-08540 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C Michael","family":"Gibson","sequence":"additional","affiliation":[{"name":"Department of Medicine at Beth Israel Deaconess Medical Center, The Baim Institute and Harvard Medical School , Boston, MA-02215 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J","family":"Mack","sequence":"additional","affiliation":[{"name":"Baylor Scott & White Health, Baylor Scott & White Research Institute , Dallas, TX-75093 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J","family":"Schneider","sequence":"additional","affiliation":[{"name":"Department of Medicine, Cardiovascular Research Institute, University of Vermont , Burlington VT-05401 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Douketis","sequence":"additional","affiliation":[{"name":"Vascular Medicine and General Internal Medicine, St. Joseph's Healthcare Hamilton, McMaster University , ON-L9C 0E3 , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank W","family":"Sellke","sequence":"additional","affiliation":[{"name":"Division of Cardiothoracic Surgery, Alpert Medical School of Brown University , Providence RI-02903 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magnus E","family":"Ohman","sequence":"additional","affiliation":[{"name":"Duke Clinical Research Institute, Duke Heart Center, Duke Program for Advanced Coronary Disease, Duke University Medical Center , Durham, NC-27701 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinod H","family":"Thourani","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Surgery, Marcus Valve Center, Piedmont Heart Institute , Atlanta, GA-30309 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert F","family":"Storey","sequence":"additional","affiliation":[{"name":"Cardiovascular Research Unit, Department of Infection, Immunity and Cardiovascular Disease, University of Sheffield , Sheffield S10 2RX , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Efthymios N","family":"Deliargyris","sequence":"additional","affiliation":[{"name":"CytoSorbents Medical Inc. 305 College Road E, Princeton, NJ-08540 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,6,3]]},"reference":[{"key":"2022120213145222600_bib1","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1177\/1753944715605011","article-title":"Factor Xa inhibitors: a novel therapeutic class for the treatment of non-valvular atrial fibrillation","volume":"10","author":"McCarty","year":"2016","journal-title":"Ther Adv Cardiovasc. Dis."},{"key":"2022120213145222600_bib2","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.ajem.2016.09.046","article-title":"Bleeding with direct oral anticoagulants vs. warfarin: clinical experience","volume":"34","author":"Eikelboom","year":"2016","journal-title":"Am J Emerg Med"},{"key":"2022120213145222600_bib3","doi-asserted-by":"crossref","first-page":"49","DOI":"10.21037\/aob.2018.12.04","article-title":"Oral anticoagulants around the world: an updated state-of-the art analysis","volume":"3","author":"Lippi","year":"2018","journal-title":"Ann Blood"},{"key":"2022120213145222600_bib4","doi-asserted-by":"crossref","first-page":"e211693","DOI":"10.1001\/jamahealthforum.2021.1693","article-title":"National trends in use of and spending on oral anticoagulants among US medicare beneficiaries from 2011 to 2019","volume":"2","author":"Troy","year":"2021","journal-title":"JAMA Health Forum"},{"key":"2022120213145222600_bib5","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","article-title":"Ticagrelor versus clopidogrel in patients with acute coronary syndromes","volume":"361","author":"Wallentin","year":"2009","journal-title":"N Engl J Med"},{"key":"2022120213145222600_bib6","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1093\/eurheartj\/ehaa575","article-title":"2020 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation","volume":"42","author":"Collet","year":"2021","journal-title":"Eur Heart J"},{"key":"2022120213145222600_bib7","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1093\/eurheartj\/ehx393","article-title":"2017 ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: the task force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the european society of cardiology (ESC)","volume":"39","author":"Ibanez","year":"2018","journal-title":"Eur Heart J"},{"key":"2022120213145222600_bib8","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1001\/jamainternmed.2018.0783","article-title":"Trends in platelet adenosine diphosphate P2Y12 receptor inhibitor use and adherence among antiplatelet-naive patients after percutaneous coronary intervention, 2008\u20132016","volume":"178","author":"Dayoub","year":"2018","journal-title":"JAMA Intern Med"},{"key":"2022120213145222600_bib9","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1093\/eurheartj\/eht013","article-title":"Antithrombotic outcome trials in acute coronary syndromes: seeking the optimal balance between safety and efficacy","volume":"34","author":"Verheugt","year":"2013","journal-title":"Eur Heart J"},{"key":"2022120213145222600_bib10","first-page":"25","article-title":"Perioperative management of direct oral anticoagulants (DOACs): a systemic review","volume":"9s1","author":"Sunkara","year":"2016","journal-title":"Health Serv. Insights"},{"key":"2022120213145222600_bib11","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1093\/eurheartj\/ehu158","article-title":"Expert position paper on the management of antiplatelet therapy in patients undergoing coronary artery bypass graft surgery","volume":"35","author":"Sousa-Uva","year":"2014","journal-title":"Eur Heart J"},{"key":"2022120213145222600_bib12","first-page":"e18","article-title":"2021 ACC\/AHA\/SCAI guideline for coronary artery revascularization: a report of the american college of cardiology\/ circulation, american heart association joint committee on clinical practice guidelines","volume":"145","author":"Lawton","year":"2022","journal-title":"Circulation"},{"key":"2022120213145222600_bib13","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1093\/ejcts\/ezx325","article-title":"2017 EACTS\/EACTA guidelines on patient blood management for adult cardiac surgery","volume":"53","author":"Pagano","year":"2018","journal-title":"Eur J Cardiothorac Surg"},{"key":"2022120213145222600_bib14","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/j.jacc.2016.11.024","article-title":"2017 ACC expert consensus decision pathway for periprocedural management of anticoagulation in patients with non-valvular atrial fibrillation: a report of the american college of cardiology clinical expert consensus document task force","volume":"69","author":"Doherty","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"2022120213145222600_bib15","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.thromres.2016.01.004","article-title":"Urgent surgery or procedures in patients taking dabigatran or warfarin: analysis of perioperative outcomes from the RE-LY trial","volume":"139","author":"Douketis","year":"2016","journal-title":"Thromb Res"},{"key":"2022120213145222600_bib16","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1056\/NEJMc1409373","article-title":"Inefficacy of platelet transfusion to reverse ticagrelor","volume":"372","author":"Godier","year":"2015","journal-title":"N Engl J Med"},{"key":"2022120213145222600_bib17","doi-asserted-by":"crossref","first-page":"103297","DOI":"10.1016\/j.transci.2021.103297","article-title":"Blood shortages and changes to massive transfusion protocols: survey of hospital practices during the COVID-19 pandemic","volume":"61","author":"Jacobs","year":"2022","journal-title":"Transfus Apher Sci"},{"key":"2022120213145222600_bib18","first-page":"206","article-title":"Role of apixaban (eliquis) in the treatment and prevention of thromboembolic disease","volume":"38","author":"Budovich","year":"2013","journal-title":"P T"},{"key":"2022120213145222600_bib19","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1016\/j.jchromb.2011.06.023","article-title":"Determination of unbound ticagrelor and its active metabolite (AR-C124910XX) in human plasma by equilibrium dialysis and LC-MS\/MS","volume":"879","author":"Sillen","year":"2011","journal-title":"J Chromatogr B"},{"key":"2022120213145222600_bib20","first-page":"e5484","article-title":"Pharmacokinetic properties of rivaroxaban in healthy human subjects","volume":"11","author":"Bratsos","year":"2019","journal-title":"Cureus"},{"key":"2022120213145222600_bib21","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1186\/s13054-019-2399-4","article-title":"Cytokine clearance with cytosorb(R) during cardiac surgery: a pilot randomized controlled trial","volume":"23","author":"Poli","year":"2019","journal-title":"Crit Care"},{"key":"2022120213145222600_bib22","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1007\/s00063-017-0342-5","article-title":"International registry on the use of the cytosorb (R) adsorber in ICU patients: study protocol and preliminary results","volume":"114","author":"Friesecke","year":"2019","journal-title":"Med Klin Intensivmed Notfmed"},{"key":"2022120213145222600_bib23","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1016\/j.cjca.2017.04.008","article-title":"Interpatient variation in rivaroxaban and apixaban plasma concentrations in routine care","volume":"33","author":"Gulilat","year":"2017","journal-title":"Can J Cardiol"},{"key":"2022120213145222600_bib24","doi-asserted-by":"crossref","first-page":"379","DOI":"10.4097\/kjae.2017.70.4.379","article-title":"Perioperative management and monitoring of antiplatelet agents: a focused review on aspirin and P2Y12 inhibitors","volume":"70","author":"Mazzeffi","year":"2017","journal-title":"Korean J Anesthesiol"},{"key":"2022120213145222600_bib25","article-title":"Cardiopulmonary bypass oxygenators 510(k) submissions - Final Guidance for industry and FDA staff","author":"US Food and Drug Administration"},{"key":"2022120213145222600_bib26","article-title":"Bioanalytical method validation guidance for industry","author":"US Food and Drug Administration"},{"key":"2022120213145222600_bib27","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1111\/bcp.12106","article-title":"Safety, pharmacokinetics and pharmacodynamics of multiple oral doses of apixaban, a factor xa inhibitor, in healthy subjects","volume":"76","author":"Frost","year":"2013","journal-title":"Br J Clin Pharmacol"},{"key":"2022120213145222600_bib28","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40262-013-0100-7","article-title":"Clinical pharmacokinetic and pharmacodynamic profile of rivaroxaban","volume":"53","author":"Mueck","year":"2014","journal-title":"Clin Pharmacokinet"},{"key":"2022120213145222600_bib29","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1159\/000484923","article-title":"Extracorporeal haemoperfusion as a potential therapeutic option for critical accumulation of rivaroxaban","volume":"45","author":"Koertge","year":"2018","journal-title":"Blood Purif."},{"key":"2022120213145222600_bib30","doi-asserted-by":"crossref","first-page":"397","DOI":"10.2165\/11599830-000000000-00000","article-title":"Pharmacokinetics and pharmacodynamics of ticagrelor in patients with stable coronary artery disease: results from the ONSET-OFFSET and RESPOND studies","volume":"51","author":"Husted","year":"2012","journal-title":"Clin Pharmacokinet"},{"key":"2022120213145222600_bib31","doi-asserted-by":"crossref","first-page":"e12518","DOI":"10.1002\/rth2.12518","article-title":"A meta-analysis of andexanet alfa and prothrombin complex concentrate in the treatment of factor Xa inhibitor-related major bleeding","volume":"5","author":"Jaspers","year":"2021","journal-title":"Res Pract Thromb Haemos"},{"key":"2022120213145222600_bib32","doi-asserted-by":"crossref","first-page":"103","DOI":"10.3390\/medicines6040103","article-title":"Direct-acting oral anticoagulants and their reversal agents-an update","volume":"6","author":"Kustos","year":"2019","journal-title":"Medicines"},{"key":"2022120213145222600_bib33","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1056\/NEJMoa1707278","article-title":"Idarucizumab for dabigatran reversal - Full cohort analysis","volume":"377","author":"Pollack","year":"2017","journal-title":"N Engl J Med"},{"key":"2022120213145222600_bib34","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1056\/NEJMoa1814051","article-title":"Investigators A-. Full study report of andexanet alfa for bleeding associated with factor xa inhibitors","volume":"380","author":"Connolly","year":"2019","journal-title":"N Engl J Med"},{"key":"2022120213145222600_bib35","first-page":"135","article-title":"Ticagrelor removal from human blood","volume":"2","author":"Angheloiu","year":"2017","journal-title":"JACC: Basic to Translational Science"},{"key":"2022120213145222600_bib36","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1177\/0267659120967827","article-title":"Cytosorb (R) haemoadsorption of apixaban during emergent cardio-pulmonary bypass: a case report","volume":"36","author":"Mendes","year":"2021","journal-title":"Perfusion"},{"key":"2022120213145222600_bib37","doi-asserted-by":"crossref","DOI":"10.5761\/atcs.oa.21-00154","article-title":"Haemoadsorption of rivaroxaban and ticagrelor during acute type a aortic dissection operations","author":"Hassan","year":"2022","journal-title":"Ann Thorac Cardiovasc Surg"},{"key":"2022120213145222600_bib38","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.athoracsur.2018.12.032","article-title":"Cytosorb adsorption during emergency cardiac operations in patients at high risk of bleeding","volume":"108","author":"Hassan","year":"2019","journal-title":"Ann Thorac Surg"},{"key":"2022120213145222600_bib39","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1053\/j.jvca.2008.08.004","article-title":"Cardiopulmonary bypass duration is an independent predictor of morbidity and mortality after cardiac surgery","volume":"22","author":"Salis","year":"2008","journal-title":"J Cardiothorac Vasc Anesth"},{"key":"2022120213145222600_bib40","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1046\/j.1525-1594.1998.06051.x","article-title":"Centrifugal pumping during routine open heart surgery improves clinical outcome","volume":"22","author":"Klein","year":"1998","journal-title":"Artif Organs"},{"key":"2022120213145222600_bib41","first-page":"71","article-title":"Predictors of post-operative bleeding and blood transfusion in cardiac surgery","volume":"43","author":"Tettey","year":"2009","journal-title":"Ghana Med J"},{"key":"2022120213145222600_bib42","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1213\/01.ANE.0000081790.75298.D8","article-title":"Blood use in patients undergoing coronary artery bypass surgery: impact of cardiopulmonary bypass pump, haematocrit, gender, age, and body weight","volume":"97","author":"Scott","year":"2003","journal-title":"Anesth & Analg"},{"key":"2022120213145222600_bib43","first-page":"280","article-title":"Risk factors of post-operative bleeding after adult cardiac surgery","volume":"19","author":"Miana","year":"2004","journal-title":"Brasileira de Cirurgia Cardiovascular"},{"key":"2022120213145222600_bib44","doi-asserted-by":"crossref","first-page":"715","DOI":"10.23736\/S0375-9393.18.12898-7","article-title":"Haemadsorption during cardiopulmonary bypass reduces interleukin 8 and tumor necrosis factor alpha serum levels in cardiac surgery: a randomized controlled trial","volume":"85","author":"Garau","year":"2019","journal-title":"Minerva Anestesiol"}],"container-title":["European Heart Journal - Cardiovascular Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ehjcvp\/advance-article-pdf\/doi\/10.1093\/ehjcvp\/pvac036\/44859396\/pvac036.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ehjcvp\/article-pdf\/8\/8\/847\/47516295\/pvac036.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ehjcvp\/article-pdf\/8\/8\/847\/47516295\/pvac036.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,2]],"date-time":"2022-12-02T08:15:32Z","timestamp":1669968932000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ehjcvp\/article\/8\/8\/847\/6601391"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,3]]},"references-count":44,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2022,6,3]]},"published-print":{"date-parts":[[2022,12,2]]}},"URL":"https:\/\/doi.org\/10.1093\/ehjcvp\/pvac036","relation":{},"ISSN":["2055-6837","2055-6845"],"issn-type":[{"value":"2055-6837","type":"print"},{"value":"2055-6845","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,12]]},"published":{"date-parts":[[2022,6,3]]}}}